Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,466,257

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic's Diagnostics Grows Strong, Escalating Costs a Woe

by Zacks Equity Research

To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.

    Here's Why You Should Invest in ResMed (RMD) Stock Right Now

    by Zacks Equity Research

    ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.

    Genomic Health's New Positive Data to Boost Test Uptake

    by Zacks Equity Research

    Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.

    QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite

    by Zacks Equity Research

    QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.

      Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

      by Zacks Equity Research

      The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.

      Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3

      by Zacks Equity Research

      Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.

      Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings

      by Zacks Equity Research

      With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.

      Here's Why You Should Invest in Genomic Health (GHDX) Now

      by Zacks Equity Research

      Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

      Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm

      by Zacks Equity Research

      Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.

      National Vision (EYE) Rides on Positive Comps Amid Cost Woes

      by Zacks Equity Research

      National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.

      STERIS (STE) Margin Pressure Hurts, Strategic Growth High

      by Zacks Equity Research

      Mounting operating expenses are weighing on the bottom line of STERIS (STE).

      TeleFlex Announces Multiple Positive Outcomes on UroLift

      by Zacks Equity Research

      A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.

      Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms

      by Zacks Equity Research

      Abbott's (ABT) EPD business operates in emerging geographies like India, Russia, China and Latin America.

      Phibro Animal Solid on Global Prospects, Currency Woes Ail

      by Zacks Equity Research

      Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.

      Henry Schein's New Buyout to Boost Dental Technology Business

      by Zacks Equity Research

      Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.

      Zimmer Biomet Solid on Global Prospects Despite Price Pressure

      by Zacks Equity Research

      Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.

      Myriad's myPath Melanoma Test Awarded Medicare Coverage

      by Zacks Equity Research

      The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.

      Align Technology (ALGN) Partners With Digital Smile Design

      by Zacks Equity Research

      Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.

      Boston Scientific's WATCHMAN FLX LAAC Device Gets CE Mark

      by Zacks Equity Research

      Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.

      HOLX vs VAR: Which MedTech Stock is a Better Investment Pick?

      by Zacks Equity Research

      Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.

      QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test

      by Zacks Equity Research

      QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.

      Here's Why You Should Add Amedisys (AMED) to Your Portfolio

      by Zacks Equity Research

      Amedisys (AMED) is currently focusing on improving clinical quality.